Assembly Biosciences (NASDAQ:ASMB) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $14.64 and traded as high as $14.96. Assembly Biosciences shares last traded at $14.90, with a volume of 11,913 shares.

Analyst Ratings Changes

Several research analysts recently commented on the company. HC Wainwright reissued a “neutral” rating on shares of Assembly Biosciences in a research note on Tuesday, September 24th. Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $2.00 to $35.00 in a research report on Friday, September 20th.

Assembly Biosciences Trading Up 1.4 %

The company has a 50-day moving average price of $15.54 and a 200-day moving average price of $14.64.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.96) by $0.98. The business had revenue of $8.53 million for the quarter, compared to analyst estimates of $5.96 million. Equities research analysts predict that Assembly Biosciences, Inc. will post -7.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ASMB. Armistice Capital LLC purchased a new stake in shares of Assembly Biosciences in the 2nd quarter valued at about $6,421,000. Renaissance Technologies LLC lifted its holdings in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 15,451 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Assembly Biosciences by 131.0% in the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 7,690 shares during the last quarter. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.